Press Release May 04, 2016

PRESS: Biosimilar Uptake in the U.S. Could Outpace Adoption in the EU (BioWorld Today)

Robert Cerwinski, a partner in Goodwin's IP Litigation Group, explains how an increase of biosimilars is likely in the U.S., but the rate of that acceleration is unpredictable. Cerwinski also discusses biosimilars conditions in the EU, where doctors are reluctant to switch patients with chronic diseases from a biologic that's working for them to a biosimilar – unless economic considerations force it.

Read the full BioWorld Today article here.